Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.

You may also be interested in...



Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent

The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.

Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent

The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.

Reimbursement Risks Driving Contingency-Based Deals, GSK Exec Says

Big pharma's appetite for low-cost, low-risk deals won't abate in 2010, as drug makers look to hedge their development bets and smaller companies need financing alternatives in a cash-constrained environment

Related Content

Topics

UsernamePublicRestriction

Register

PS067119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel